Growth hormone response to clonidine predicts aggression in Alzheimer's disease

Psychoneuroendocrinology

Volumn 29, Issue 9, 2004, Pages 1192-1197

  Herrmann, Nathan ^a,d   Lanctôt, Krista L ^a,d,e   Eryavec, Goran ^b,d   Van Reekum, Robert ^c,d   Khan, Lyla R ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NORTH YORK GENERAL HOSPITAL   (Canada)

^c BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aggression; Alzheimer's disease; Behavioral and psychological symptoms of dementia; Neurochemical pathology; Norepinephrine

Indexed keywords

CLONIDINE; GROWTH HORMONE;

ADULT; AGGRESSION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; DRUG EFFECT; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PREDICTION; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; AGED; AGED, 80 AND OVER; AGGRESSION; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; BRAIN; CLONIDINE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PREDICTIVE VALUE OF TESTS; STIMULATION, CHEMICAL;

EID: 3042681768     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2004.02.001     Document Type: Article

References (43)

1. Alexopoulos G.S., Abrams R.C., Young R.C., Shamoian C.A. Cornell Scale for Depression in Dementia. Biol. Psychiatry. 23:1988;271-284
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1994;American Psychiatric Association, Washington, DC
3. Anand A., Charney D.S. Norepinephrine dysfunction in depression. J. Clin. Psychiatry. 61:2000;16-24
4. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schmeidler J., Kanof P., Davis K.L. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64:1995;749-760
5. Bondareff W., Mountjoy C.Q., Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 32:1982;164-168
6. Chan-Palay V., Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287:1989;373-392
7. Charney D.S., Heninger G.R. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry. 43:1986;1042-1054
8. Charney D.S., Heninger G.R., Sternberg D.E., Hafstad K.M., Giddings S., Landis D.H. Adrenergic receptor sensitivity in depression. Effects of clonidine in depressed patients and healthy subjects. Arch. Gen. Psychiatry. 39:1982;290-294
9. Coccaro E.F., Lawrence T., Trestman R., Gabriel S., Klar H.M., Siever L.J. Growth hormone responses to intravenous clonidine challenge correlate with behavioral irritability in psychiatric patients and healthy volunteers. Psychiatry Res. 39:1991;129-139
10. Cohen-Mansfield J., Billig N. Agitated behaviors in the elderly. I. A conceptual review. J. Am. Geriatr. Soc. 34:1986;711-721
11. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 44:1994;2308-2314
12. Eriksson E., Eden S., Modigh K. Up- and down-regulation of central postsynaptic alpha 2 receptors reflected in the growth hormone response to clonidine in reserpine-pretreated rats. Psychopharmacology. 77:1982;327-331
13. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198
14. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., Neary D., Snowden J.S., Wilcock G.K. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 313:1985;7-11
15. Gerra G., Zaimovic A., Avanzini P., Chittolini B., Giucastro G., Caccavari R., Palladino M., Maestri D., Monica C., Delsignore R., Brambilla F. Neurotransmitter-neuroendocrine responses to experimentally induced aggression in humans: influence of personality variable. Psychiatry Res. 66:1997;33-43
16. Gil-Ad I., Gurewitz R., Marcovici O., Rosenfeld J., Laron Z. Effect of aging on human plasma growth hormone response to clonidine. Mech. Ageing Dev. 27:1984;97-100
17. Gilles C., Ryckaert P., de Mol J., de Maertelaere V., Mendlewicz J. Clonidine-induced growth hormone secretion in elderly patients with senile dementia of the Alzheimer type and major depressive disorder. Psychiatry Res. 27:1989;277-286
18. Glass I.B., Checkley S.A., Shur E., Dawling S. The effect of desipramine upon central adrenergic function in depressed patients. Br. J. Psychiatry. 141:1982;372-376
19. Hachinski V.C., Iliff L.D., Zilhka E., Du Boulay G.H., McAllister V.L., Marshall J., Russell R.W., Symon L. Cerebral blood flow in dementia. Arch. Neurol. 32:1975;632-637
20. Haller J., Makara G.B., Kruk M.R. Catecholaminergic involvement in the control of aggression: hormones, the peripheral sympathetic, and central noradrenergic systems. Neurosci. Biobehav. Rev. 22:1998;85-97
21. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can. J. Neurol. Sci. 28:(Suppl. 1):2001;S96-S107
22. Herrmann N., Lanctôt K.L. From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Can. J. Psychiatry. 42:(Suppl. 1):1997;51S-64S
23. Hoogendijk W.J., Feenstra M.G., Botterblom M.H., Gilhuis J., Sommer I.E., Kamphorst W., Eikelenboom P., Swaab D.F. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 45:1999;82-91
24. Lanctôt K.L., Herrmann N., Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 13:2001;5-21
25. Mann D.M., Yates P.O., Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry. 45:1982;113-119
26. Matthews K.L., Chen C.P., Esiri M.M., Keene J., Minger S.L., Francis P.T. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry. 51:2002;407-416
27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944
28. Mongeau R., de Montigny C., Blier P. Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology. 10:1994;41-51
29. Nickola T.J., Ignatowski T.A., Reynolds J.L., Spengler R.N. Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. J. Pharmacol. Exp. Ther. 297:2001;680-687
30. Nutt D.J. Neurobiological mechanisms in generalized anxiety disorder. J. Clin. Psychiatry. 62:2001;22-27. discussion 28
31. Nyback H., Nyman H., Schalling D. Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia. Acta Psychiatr. Scand. 76:1987;648-656
32. Palmer A.M., Francis P.T., Bowen D.M., Benton J.S., Neary D., Mann D.M., Snowden J.S. Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res. 414:1987;365-375
33. Peskind E.R., Wingerson D., Murray S., Pascualy M., Dobie D.J., Le Corre P., Le Verge R., Veith R.C., Raskind M.A. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch. Gen. Psychiatry. 52:1995;774-782
34. Rabins P.V., Mace N.L., Lucas M.J. The impact of dementia on the family. Jama. 248:1982;333-335
35. Raskind M.A., Peskind E.R., Halter J.B., Jimerson D.C. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch. Gen. Psychiatry. 41:1984;343-346
36. Raskind M.A., Peskind E.R., Holmes C., Goldstein D.S. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol. Psychiatry. 46:1999;756-765
37. Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J. Neurosci. 17:1997;5573-5580
38. Siever L.J., Uhde T.W. New studies and perspectives on the noradrenergic receptor system in depression: effects of the alpha 2-adrenergic agonist clonidine. Biol. Psychiatry. 19:1984;131-156
39. Sorgi P., Ratey J., Knoedler D.W., Markert R.J., Reichman M. Rating aggression in the clinical setting. A retrospective adaptation of the Overt Aggression Scale: preliminary results. J. Neuropsychiatry Clin. Neurosci. 3:1991;S52-S56
40. Szot P., Leverenz J.B., Peskind E.R., Kiyasu E., Rohde K., Miller M.A., Raskind M.A. Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the locus coeruleus in Alzheimer's disease. Brain Res. Mol. Brain Res. 84:2000;135-140
41. Uhde T.W., Vittone B.J., Siever L.J., Kaye W.H., Post R.M. Blunted growth hormone response to clonidine in panic disorder patients. Biol. Psychiatry. 21:1986;1081-1085
42. Valdivieso S., Duval F., Mokrani M.C., Schaltenbrand N., Castro J.O., Crocq M.A., Macher J.P. Growth hormone response to clonidine and the cortisol response to dexamethasone in depressive patients. Psychiatry Res. 60:1996;23-32
43. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60:2003;337-341